http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004039391-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27bb0102d35098b33576852c8183ddc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_073f1e6028b2fdcc761d84401f8902c1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2003-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29536793e7e01eafb2c5d9f534f67fa2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cafccd7cc94c984bd1afd09031381830 |
| publicationDate | 2004-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2004039391-A1 |
| titleOfInvention | Viral serpin regulation of inflamation |
| abstract | The present invention provides for a pharmaceutical composition containing at least one compound that promotes intracellular signalling via the human urokinase plasminogen activator receptor. The compound binds the human urokinase plasminogen activator receptor, the compound binds one or more intracellular protein(s) directly or indirectly associated with intracellular signalling via human urokinase plasminogen activator receptor, and the compound binds one or more intracellular protein(s) that are modulated by urokinase plasminogen activator receptor activity. The compound is an organic or inorganic compound with a molecular weight less than 1kDa, compound is a peptide between 2 and 20 amino acids in length, and the compound is a polypeptide greater than 20 amino acids in length. The compound is an antibody or fragment thereof, the compound is a nucleic acid, and the compound is administered to humans in vivo, and to human cells ex vivo. The composition includes a pharmaceutically acceptable carrier, and the composition is administered to a human individual for the treatment of an inflamatory condition. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7419670-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7745396-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7906483-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7514405-B2 |
| priorityDate | 2002-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.